Bio Research

We are an unparalleled biopharmaceutical company.



SDR-grafting Technology minimizes the mouse-derived amino acid sequence compared to the existing CDR-grafting technology, which in turn minimizes the side-effects caused by the body's immune response even after long-term administration of a drug.

  • Patent TitleHumanized antibody and process for preparing same
  • Patent No.US8420353B2
  • Patent Link

SDR-GraftingPopup close

SDR-grafting Technology minimizes the immune response elicited from an individual by selectively extracting the SDR (Specificity-Determining Residues) from the CDR (Complementarity-Determining Region) of a mouse-derived monoclonal antibody that is shown to have a therapeutic effect and transplanting the SDR into a human antibody.

Conventional antibody humanization technologies have used chimeric antibody manufacturing techniques for transplanting the entire variable region to human antibodies, or techniques such as CDR-grafting and CDR-walking for transplanting the CDRs within the variable regions. SDR-grafting is a more advanced technology that extracts only the specific amino acids within the CDRs that are critical in binding and transplants them into human antibodies.

Mouse-derived monoclonal antibodies commonly induce excessive immune responses in humans towards the foreign amino acid sequences with repeated administrations. This, in turn, causes a gradual decrease in the therapeutic efficacy and clinical side-effects. Hence, the current trend is to minimize mouse-derived amino acid sequences using antibody humanization technologies to produce chimeric or humanized antibodies. Comparing with the existing technologies, our SDR-grafting technology is most effective in reducing the foreign amino acid sequences.